Virtual Reality-Enhanced Rehabilitation for Cognitive Recovery in Acute Post-Stroke Patients: Pilot Study
VR
Effects of Virtual Reality-Enhanced Rehabilitation on Cognitive Recovery in Acute Post-Stroke Patients: a Pilot Study
2 other identifiers
interventional
36
1 country
1
Brief Summary
Post-stroke rehabilitation is essential for maximising motor recovery. Virtual reality (VR) is emerging as a promising adjunct to conventional therapy (CRT), potentially enhancing upper limb motor outcomes. The goal of the study is to investigate the impact of virtual reality rehabilitation compared to conventional rehabilitation therapy on cognitive function and activities of daily living in patients with acute stroke.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started May 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 5, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 10, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 24, 2025
CompletedFirst Submitted
Initial submission to the registry
January 24, 2026
CompletedFirst Posted
Study publicly available on registry
February 2, 2026
CompletedFebruary 12, 2026
January 1, 2026
1.1 years
January 24, 2026
February 9, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
The Mini-Mental State Examination (MMSE)
It is a widely used screening tool for global cognitive function. It evaluates orientation, immediate registration and short-term recall, attention and calculation, and language and praxis. The total score ranges from 0 to 30, and scores below 24 are commonly interpreted as suggestive of cognitive impairment.
Change from baseline to 2 weeks (end of intervention)
The Barthel Index (BI)
The Barthel Index (BI) evaluates an individual's level of independence and mobility in activities of daily living (ADLs), including feeding, bathing, grooming, dressing, bowel and bladder control, toileting, transfers, walking/ambulation, and stair climbing. It also helps determine the degree of assistance required for care.
Change from baseline to 2 weeks (end of intervention)
Secondary Outcomes (2)
The National Institutes of Health Stroke Scale (NIHSS)
Change from baseline to 2 weeks (end of intervention)
The Modified Rankin Scale (mRS)
Change from baseline to 2 weeks (end of intervention)
Study Arms (2)
VR + CRT (Virtual reality-enhanced rehabilitation plus Conventional rehabilitation therapy)
EXPERIMENTALThe experimental group will receive physiotherapy and occupational therapy (manual therapy techniques, passive and active-assisted mobilisation, scapular mobilisation, and task-specific training such as horizontally moving an object across a surface), ten sessions over two weeks of 60 minutes per session and an additional 15 minutes of virtual-reality (VR) training per session using the Bimeo PRO system (Kinestica d.o.o., Slovenia) in a unimanual, two-dimensional configuration on a flat surface, with continuous therapist supervision.
CRT (Conventional rehabilitation therapy)
ACTIVE COMPARATORThe control group will receive 10 sessions over 2 weeks of physiotherapy and occupational therapy (manual therapy techniques, passive and active-assisted mobilisation, scapular mobilisation, and task-specific training, such as moving an object horizontally across a surface), each lasting 60 minutes.
Interventions
Dose of practice and difficulty: In each VR session, participants will perform two tasks, completing one trial of each-a memory task and a meal-preparation task -with no within-session repetitions. Over ten sessions, participants will complete 10 trials of each task (30 in total). Task difficulty will be fixed and identical for all participants throughout the intervention (no automatic progression or therapist-driven difficulty changes). Adherence, tolerability, and adverse events: Participants will be scheduled to complete the prescribed VR dose (10 sessions; 150 minutes total). Adherence will be recorded at each session. Serious adverse events are not expected; all adverse events will be actively monitored and documented.
Physiotherapy and occupational therapy: manual therapy techniques, passive and active-assisted mobilisation, scapular mobilisation, and task-specific training, such as horizontally moving an object across a surface, 60 minutes per session.
Eligibility Criteria
You may qualify if:
- Adults ≥18 years.
- First-ever acute stroke, occurring \<7 days before therapy start
- Cognitive impairment on admission (Mini-Mental State Examination score \< 24
- Ability to understand and perform virtual reality (VR) tasks.
You may not qualify if:
- Severe cognitive impairment that precludes following instructions.
- Aphasia or severe visual/hearing impairment that prevents meaningful participation.
- End-stage/terminal illness.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University Medical Centre Maribor, Ljubljanska 5 Maribor, Slovenia
Maribor, 2000, Slovenia
Related Links
Study Officials
- PRINCIPAL INVESTIGATOR
Tadeja Hernja Rumpf
University Medical Centre Maribor, Slovenia
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- INVESTIGATOR
- Masking Details
- Therapists who will evaluate participants with scales will be blinded to group allocation.
- Purpose
- TREATMENT
- Intervention Model
- FACTORIAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
January 24, 2026
First Posted
February 2, 2026
Study Start
May 5, 2024
Primary Completion
June 10, 2025
Study Completion
September 24, 2025
Last Updated
February 12, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share
IPD will not be shared due to the small sample size and increased re-identification risk under GDPR. Aggregate results, study protocol, and statistical analysis plan will be made available upon publication.